Table 1.
Patient demographics and clinical profile.
| Clinical variables | Study population (n = 252) |
|---|---|
| Age, (years) | |
| Median (min, max) | 67 (28–99) |
| Gender, n (%) | |
| Male | 154 (61%) |
| Female | 98 (39%) |
| Number of metastatic sites, n (%) | |
| 1 site | 96 (38%) |
| > 1 site | 156 (62%) |
| Liver metastasis | |
| Yes | 157 (62%) |
| No | 94 (37%) |
| Unknown | 1 (< 1%) |
| Performance status, n (%) | |
| 0 | 165 (65%) |
| 1 | 72 (29%) |
| ≥ 2 | 19 (4%) |
| Unknown | 6 (2%) |
| Line of palliative chemotherapy, n (%) | |
| First | 132 (52%) |
| Second or later | 120 (48%) |
| Primary tumor resected at baseline, n (%) | 138 (55%) |
| Carcinoembryonic antigen, n (%) | |
| ≤ 5 ug/L | 35 (14%) |
| > 5 ug/L | 150 (59%) |
| Unknown | 67 (27%) |
| Lactate dehydrogenase, n (%) | |
| ≤ 205 U/L | 104 (41%) |
| > 205 U/L | 124 (49%) |
| Unknown | 24 (10%) |
| Platelets, n (%) | |
| ≤ 390 × 109/L | 216 (86%) |
| > 390 × 109/L | 31 (12%) |
| Unknown | 5 (2%) |
| Neutrophils, n (%) | |
| ≤ 5.9 × 109/mL | 146 (58%) |
| > 5.9 × 109/mL | 51 (20%) |
| Unknown | 55 (22%) |
| White blood cells, n (%) | |
| ≤ 8.8 × 109/mL | 190 (75%) |
| > 8.8 × 109/mL | 57 (23%) |
| Unknown | 5 (2%) |